Literature DB >> 16079296

Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation.

Jon G Mabley1, Eszter M Horváth, Kanneganti G K Murthy, Zsuzsanna Zsengellér, Anne Vaslin, Rita Benko, Márk Kollai, Csaba Szabó.   

Abstract

Activation of poly(ADP-ribose) polymerase (PARP) is an important factor in the pathogenesis of various cardiovascular and inflammatory diseases. Here, we report that the gender-specific inflammatory response is preferentially down-regulated by PARP in male animals. Female mice produce less tumor necrosis factor-alpha and macrophage inflammatory protein-1alpha in response to systemic inflammation induced by endotoxin than male mice and are resistant to endotoxin-induced mortality. Pharmacological inhibition of PARP is effective in reducing inflammatory mediator production and mortality in male, but not in female, mice. Ovariectomy partially reverses the protection seen in female mice. Endotoxin-induced PARP activation in circulating leukocytes is reduced in male, but not female, animals by pharmacological PARP inhibition, as shown by flow cytometry. Pretreatment of male mice with 17-beta-estradiol prevents endotoxin-induced hepatic injury and reduces poly(ADP-ribosyl)ation in vivo. In male, but not female, animals, endotoxin induces an impairment of the endothelium-dependent relaxant responses, which is prevented by PARP inhibition. In vitro oxidant-induced PARP activation is reduced in cultured cells placed in female rat serum compared with male serum. Estrogen does not directly inhibit the enzymatic activity of PARP in vitro. However, PARP and estrogen receptor alpha form a complex, which binds to DNA in vitro, and the DNA binding of this complex is enhanced by estrogen. Thus, estrogen may anchor PARP to estrogen receptor alpha and to the DNA and prevent its recognition of DNA strand breaks and hence its activation. In conclusion, the gender difference in the inflammatory response shows preferential modulation by PARP in male animals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16079296     DOI: 10.1124/jpet.105.090480

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  54 in total

Review 1.  Oxidative stress and NAD+ in ischemic brain injury: current advances and future perspectives.

Authors:  W Ying; Z-G Xiong
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

2.  The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.

Authors:  Akbar Ahmad; Gabor Olah; David N Herndon; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-05       Impact factor: 8.739

Review 3.  Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction.

Authors:  Csaba Szabo
Journal:  Br J Pharmacol       Date:  2009-02-06       Impact factor: 8.739

4.  Regulation of mitochondrial poly(ADP-Ribose) polymerase activation by the β-adrenoceptor/cAMP/protein kinase A axis during oxidative stress.

Authors:  Attila Brunyanszki; Gabor Olah; Ciro Coletta; Bartosz Szczesny; Csaba Szabo
Journal:  Mol Pharmacol       Date:  2014-07-28       Impact factor: 4.436

5.  Renal hypoperfusion and impaired endothelium-dependent vasodilation in an animal model of VILI: the role of the peroxynitrite-PARP pathway.

Authors:  Rosanna Vaschetto; Jan W Kuiper; René J P Musters; Etto C Eringa; Francesco Della Corte; Kanneganti Murthy; A B Johan Groeneveld; Frans B Plötz
Journal:  Crit Care       Date:  2010-03-26       Impact factor: 9.097

Review 6.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

7.  The Angiotensin-converting enzyme inhibitor captopril inhibits poly(adp-ribose) polymerase activation and exerts beneficial effects in an ovine model of burn and smoke injury.

Authors:  Sven Asmussen; Eva Bartha; Gabor Olah; Elena Sbrana; Sebastian W Rehberg; Yusuke Yamamoto; Perenlei Enkhbaatar; Hal K Hawkins; Hiroshi Ito; Robert A Cox; Lillian D Traber; Daniel L Traber; Csaba Szabo
Journal:  Shock       Date:  2011-10       Impact factor: 3.454

8.  Differential gender effects of a reduced-calorie diet on systemic inflammatory and immune parameters in nonhuman primates.

Authors:  J L Ebersole; M J Steffen; M A Reynolds; G L Branch-Mays; D R Dawson; K F Novak; J C Gunsolley; J A Mattison; D K Ingram; M J Novak
Journal:  J Periodontal Res       Date:  2008-06-28       Impact factor: 4.419

9.  PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males.

Authors:  Xue Mei Jin; Hee Nam Kim; Il-Kwon Lee; Kyeong-Soo Park; Hyeoung-Joon Kim; Jin-Su Choi; Sang Woo Juhng; Chan Choi
Journal:  BMC Med Genet       Date:  2010-03-03       Impact factor: 2.103

10.  Time course of nitric oxide synthases, nitrosative stress, and poly(ADP ribosylation) in an ovine sepsis model.

Authors:  Matthias Lange; Rhykka Connelly; Daniel L Traber; Atsumori Hamahata; Yoshimitsu Nakano; Aimalohi Esechie; Collette Jonkam; Sanna von Borzyskowski; Lillian D Traber; Frank C Schmalstieg; David N Herndon; Perenlei Enkhbaatar
Journal:  Crit Care       Date:  2010-07-05       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.